- Overview:
- Treatment is driven first by p16 / HPV status:
- Which assigns separate AJCC 8th edition staging, and then by T / N category:
- With the overarching NCCN principle of:
- Using the fewest modalities necessary to control disease while preserving speech and swallowing and avoiding triple-modality therapy (surgery + RT + chemotherapy) whenever possible (NCCN, Head and Neck Cancers, 2026; Dunn et al., JAMA, 2026)
- With the overarching NCCN principle of:
- Which assigns separate AJCC 8th edition staging, and then by T / N category:
- For a resectable primary:
- Upfront surgery (increasingly TORS) and definitive radiation ☢️ or chemoradiation are both curative-intent options with comparable survival in HPV-positive disease:
- The choice is a shared decision balancing functional outcomes (Nichols et al., Journal of Clinical Oncology, 2024; Hoenle et al., European Archives of Oto-Rhino-Laryngology, 2026)
- Upfront surgery (increasingly TORS) and definitive radiation ☢️ or chemoradiation are both curative-intent options with comparable survival in HPV-positive disease:
- Two absolute surgical caveats from NCCN:
- Patients with fixed or matted nodes or obvious extranodal extension (ENE):
- Are not candidates for upfront definitive surgery:
- Concurrent chemoradiation is preferred
- Are not candidates for upfront definitive surgery:
- T4b or unresectable disease:
- Goes to definitive systemic therapy / RT (NCCN, Head and Neck Cancers, 2026).
- Patients with fixed or matted nodes or obvious extranodal extension (ENE):
- Treatment is driven first by p16 / HPV status:
- p16 Testing and Staging (First Branch Point):
- NCCN requires p16 IHC on every oropharyngeal tumor:
- With positivity defined as ≥70% nuclear and cytoplasmic staining of moderate-to-strong intensity
- Confirmatory direct HPV testing (PCR or RNA-ISH) is recommended:
- Particularly because p16+ / HPV– discordant tumors:
- Behave more like p16-negative disease
- Particularly because p16+ / HPV– discordant tumors:
- p16-positive tumors:
- Are staged separately and assigned substantially lower stages:
- Reflecting their better prognosis and radiosensitivity (NCCN, Head and Neck Cancers, 2026; Mehanna et al., Lancet Oncology, 2023)
- Are staged separately and assigned substantially lower stages:
- NCCN requires p16 IHC on every oropharyngeal tumor:
- Surgery: Open vs TORS
- Oncologic principles are identical to open resection:
- But transoral approaches (TORS / TLM) avoid transmandibular / transcervical incisions and yield markedly better functional outcomes:
- Lower tracheostomy and feeding-tube rates, less free-flap reconstruction, shorter stay, and faster return of swallowing :
- Without a difference in margins or survival in comparative series (Park et al., European Journal of Surgical Oncology, 2020; Roselló et al., Medicina Oral Patología Oral y Cirugía Bucal, 2020; Cramer et al., Nature Reviews Clinical Oncology, 2019)
- Lower tracheostomy and feeding-tube rates, less free-flap reconstruction, shorter stay, and faster return of swallowing :
- But transoral approaches (TORS / TLM) avoid transmandibular / transcervical incisions and yield markedly better functional outcomes:
- The randomized ORATOR trial (T1 to T2, N0 to N2):
- Found no difference in overall or progression-free survival between primary RT and TORS at 5 years
- Toxicity profiles differed:
- More xerostomia with RT
- More pain / dysphagia with TORS:
- So modality choice remains a shared decision (Nichols et al., Journal of Clinical Oncology, 2024)
- The 2025 ASCO TORS guideline frames candidacy (Holsinger et al., Journal of Clinical Oncology, 2025):
- TORS should be discussed for T1 to T2 tumors:
- When preoperative multimodal assessment predicts a high probability of R0 resection
- Select exophytic T3 tumors:
- Where resection will not cause significant functional deficit may be considered (off-label), case-by-case within a multidisciplinary team
- T4 tumors should not be offered transoral surgery alone
- Contraindications / limitations to adequate exposure:
- Trismus from pterygoid muscle invasion, narrow mandibular arch or tori, and tumors where pharyngeal vessels cannot be controlled (bleeding risk)
- Exposure should be confirmed in-office and again under anesthesia.
- TORS should be discussed for T1 to T2 tumors:
- Open surgery remains appropriate:
- When exposure, tumor size / location, defect management, or reconstruction needs make transoral resection inadequate:
- The approach should be dictated by these factors and surgeon experience, not by a blanket preference
- When exposure, tumor size / location, defect management, or reconstruction needs make transoral resection inadequate:
- Oncologic principles are identical to open resection:
- A key rationale for upfront TORS in HPV-positive disease is:
- Pathology-guided de-escalation of adjuvant therapy:
- In ECOG 3311:
- ~ 70% of patients were safely spared standard-intensity adjuvant therapy, and 5-year OS was 95% (Holsinger et al., Journal of Clinical Oncology, 2025; Mody et al., Lancet, 2021)
- In ECOG 3311:
- Pathology-guided de-escalation of adjuvant therapy:
- Neck Dissection: When and How Much:
- Any patient treated with upfront surgery for the primary:
- Should undergo concurrent neck dissection (Koyfman et al., Journal of Clinical Oncology, 2019)
- Lateralized tumors:
- Ipsilateral selective neck dissection of levels II to IV, with an adequate yield of ≥ 18 lymph nodes (a quality metric associated with better survival and locoregional control) (NCCN, Head and Neck Cancers, 2026; Koyfman et al., Journal of Clinical Oncology, 2019)
- Bilateral neck dissection:
- For tumors of the base of tongue, soft palate, posterior pharyngeal wall, or lesions at /approaching midline (and tonsil tumors invading the tongue base) — unless bilateral adjuvant RT is already planned
- If TORS is chosen for a near-midline tongue base tumor, contralateral nodal management must be addressed, sometimes staged (Holsinger et al., Journal of Clinical Oncology, 2025; NCCN, Head and Neck Cancers, 2026)
- Extent by nodal stage:
- N0 → selective (oropharynx ≥ levels II to IV)
- N1 to N2a–c → selective or comprehensive
- N3 → comprehensive (NCCN, Head and Neck Cancers, 2026)
- For pN0 to pN1 without adverse features:
- Favor single-modality treatment:
- Lateralized pN0 to pN1 with favorable pathology can be observed, and a staged contralateral neck dissection can be used to avoid RT in midline tumors resected to clean margins (NCCN, Head and Neck Cancers, 2026)
- Favor single-modality treatment:
- Any patient treated with upfront surgery for the primary:
- Radiation Alone vs Definitive Chemoradiation
- When nonsurgical treatment is chosen:
- The distinction hinges on T and N category (indications derive from AJCC-7-era trial eligibility)
- Definitive RT is 66 to 70 Gy
- Concurrent chemoradiation uses 70 Gy with high-dose cisplatin 100 mg/m² every 3 weeks (category 1), with weekly cisplatin 40 mg/m² or carboplatin / 5-FU as alternatives (NCCN, Head and Neck Cancers, 2026; Dunn et al., JAMA, 2026)
- RT alone:
- Is appropriate for early, low-volume disease:
- T1 to T2N0, and T1N1 (single node ≤ 3 cm)
- A large Swedish registry analysis supports RT alone as safe for T1 to T2N1 to N2a disease (Margalit et al., Practical Radiation Oncology, 2024; Gooi et al., Head & Neck, 2016; Adrian et al., International Journal of Radiation Oncology Biology Physics, 2026)
- T2N1 (single node ≤ 3 cm):
- Either RT alone or concurrent chemoRT is acceptable (NCCN lists concurrent chemoRT as category 2B here) (Margalit et al., Practical Radiation Oncology, 2024; NCCN, Head and Neck Cancers, 2026)
- Concurrent chemoradiation is recommended for all fit patients with T3 to T4 disease, ≥ 2 positive nodes, or a single node > 3 cm, based on OS / locoregional-control benefit across multiple trials (AJCC-7 stage III–IV ≈ AJCC-8 T1–2N1–3 and T3–4N0–3):
- ASTRO emphasizes that when systemic therapy is warranted it must be concurrent, not induction / sequential, and cisplatin is standard — cetuximab is inferior for recurrence and survival (Margalit et al., Practical Radiation Oncology, 2024; Gooi et al., Head & Neck, 2016)
- Is appropriate for early, low-volume disease:
- HPV status does not change the choice of systemic agent:
- Ot is prognostic, not predictive, and no de-escalation regimen (cetuximab substitution or dose reduction to 60 Gy) has proven non-inferior to 70 Gy + cisplatin in phase III;
- So de-escalation stays within trials (Holsinger et al., Journal of Clinical Oncology, 2025; Margalit et al., Practical Radiation Oncology, 2024; Petrelli et al., European Archives of Oto-Rhino-Laryngology, 2023)
- Ot is prognostic, not predictive, and no de-escalation regimen (cetuximab substitution or dose reduction to 60 Gy) has proven non-inferior to 70 Gy + cisplatin in phase III;
- Induction chemotherapy before RT / chemoRT remains category 3 in NCCN (NCCN, Head and Neck Cancers, 2026; Gooi et al., Head & Neck, 2016)
- When nonsurgical treatment is chosen:
- Adjuvant Therapy After Surgery (Pathology-Directed):
- Adverse features determine escalation:
- ENE and / or positive margin:
- Concurrent systemic therapy / RT (the high-risk indication established in RTOG 9501 / EORTC 22931, in largely HPV-unselected populations) (NCCN, Head and Neck Cancers, 2026)
- Positive margin alone → re-resection if feasible, or RT, or chemoRT (NCCN, Head and Neck Cancers, 2026)
- ENE and / or positive margin:
- Other risk features (close margins < 3 mm, pT3 to pT4, multiple nodes or node > 3 cm, level IV / V nodes, PNI, LVI):
- RT, or consider chemoRT (NCCN, Head and Neck Cancers, 2026)
- Postoperative RT is:
- 60 to 66 Gy for high-risk sites:
- Ideally started ≤ 6 weeks after surgery (NCCN, Head and Neck Cancers, 2026)
- 60 to 66 Gy for high-risk sites:
- In p16-positive disease the value of adding chemotherapy for ENE / positive margins is actively debated:
- A propensity-matched analysis found no OS difference between adjuvant RT and chemoRT — and NCCN permits de-escalation to 50 Gy for selected intermediate-risk p16+ patients:
- ECOG 3311 criteria:
- ≤ 4 positive nodes ≤ 6 cm
- T1 to T2 resected to negative / close margins with ≤ 1 mm ENE; category 2 (Fenlon et al., Head & Neck, 2022; NCCN, Head and Neck Cancers, 2026)
- ECOG 3311 criteria:
- A propensity-matched analysis found no OS difference between adjuvant RT and chemoRT — and NCCN permits de-escalation to 50 Gy for selected intermediate-risk p16+ patients:
- Adverse features determine escalation:
- Response Assessment and the Neck After Chemoradiation:
- Response is evaluated with FDG-PET / CT:
- Obtained ≥ 12 weeks after chemoradiation (Dunn et al., JAMA, 2026)
- The PET-NECK randomized trial established PET / CT-guided surveillance rather than planned neck dissection for N2 to N3 disease:
- It reduced operations with equivalent survival (Dunn et al., JAMA, 2026):
- Patients with a complete metabolic response are observed
- Those with residual / avid nodal disease proceed to salvage neck dissection
- Equivocal findings may be followed with serial imaging (Koyfman et al., Journal of Clinical Oncology, 2019)
- It reduced operations with equivalent survival (Dunn et al., JAMA, 2026):
- Response is evaluated with FDG-PET / CT:
- Salvage Surgery:
- For resectable locoregional recurrence, persistent disease, or a second primary after definitive (chemo)RT:
- Salvage surgery is the cornerstone and often the only curative option:
- Regardless of prior radiation (Fulcher et al., Head & Neck, 2018; Ward et al., Journal of the National Cancer Institute, 2026)
- Salvage surgery is the cornerstone and often the only curative option:
- Patient selection is paramount:
- Candidacy and outcome depend on recurrent T/N stage, site, disease-free interval, initial treatment, and locoregional vs limited local extent, weighed against significant functional morbidity (loss of larynx / pharynx function, tracheostomy / gastrostomy dependence) (Fulcher et al., Head & Neck, 2018; Patel et al., Head & Neck, 2016; Gañán et al., European Archives of Oto-Rhino-Laryngology, 2016)
- HPV-positive recurrences salvage better:
- In a secondary analysis of RTOG 1016, salvage surgery after locoregional failure improved 5-year OS versus no surgery (45% vs 17%) with acceptable late toxicity; salvage reduces death risk ~ 50%, with p16+ outperforming p16– (Lim et al., Oncogene, 2023; Quan et al., Cancer, 2023)
- TORS is an increasingly used salvage option:
- Within a previously irradiated field (weak evidence, strong ASCO recommendation) for appropriately selected, usually pT1 to pT2 recurrences, offering lower tracheostomy / gastrostomy dependence than open salvage:
- The RECUT cohort showed 5-year local control ~ 62% and OS ~ 50%, with margins < 1 mm the strongest adverse factor
- Larger recurrences require open resection, often with free-flap reconstruction that also introduces non-irradiated tissue to facilitate re-irradiation (Holsinger et al., Journal of Clinical Oncology, 2025; Ward et al., Journal of the National Cancer Institute, 2026; de Groot et al., Annals of Otology Rhinology & Laryngology, 2025)
- Within a previously irradiated field (weak evidence, strong ASCO recommendation) for appropriately selected, usually pT1 to pT2 recurrences, offering lower tracheostomy / gastrostomy dependence than open salvage:
- After salvage:
- Manage by pathologic risk features:
- Re-irradiation (± chemotherapy) improves local control but adds substantial toxicity without a clear OS benefit, so it is individualized (Fulcher et al., Head & Neck, 2018; Leddon et al., Clinical Cancer Research, 2022).
- Manage by pathologic risk features:
- For resectable locoregional recurrence, persistent disease, or a second primary after definitive (chemo)RT:
- Works Cited:
Adrian, G., et al. “Chemoradiation Therapy Versus Radiation Therapy Alone in T1-2 Oropharyngeal Cancer With Low-Volume Neck Disease: A Population-Based Cohort Study Using the Swedish Head and Neck Cancer Register.” International Journal of Radiation Oncology Biology Physics, 2026.
Cramer, J. D., et al. “The Changing Therapeutic Landscape of Head and Neck Cancer.” Nature Reviews Clinical Oncology, 2019.
de Groot, E. C. M., et al. “Salvage Transoral Robotic Surgery With Submental Flap Reconstruction: Functional and Oncologic Outcomes.” Annals of Otology, Rhinology & Laryngology, 2025.
Dunn, L. A., A. L. Ho, and D. G. Pfister. “Head and Neck Cancer: A Review.” JAMA, 2026.
Fenlon, J. B., et al. “Comparing Adjuvant Radiation to Adjuvant Chemoradiation in Postsurgical p16+ Oropharyngeal Carcinoma Patients With Extranodal Extension or Positive Margins.” Head & Neck, 2022.
Fulcher, C. D., M. Haigentz, and T. J. Ow. “AHNS Series: Do You Know Your Guidelines? Principles of Treatment for Locally Advanced or Unresectable Head and Neck Squamous Cell Carcinoma.” Head & Neck, 2018.
Gañán, L., et al. “Management of Recurrent Head and Neck Cancer: Variables Related to Salvage Surgery.” European Archives of Oto-Rhino-Laryngology, 2016.
Gooi, Z., et al. “AHNS Series: Do You Know Your Guidelines? Principles of Radiation Therapy for Head and Neck Cancer: A Review of the National Comprehensive Cancer Network Guidelines.” Head & Neck, 2016.
Hoenle, A., et al. “HPV-Specific Treatment Trends in Oropharyngeal Squamous Cell Carcinoma: A Population-Based Analysis With Stage-Stratified Interaction Testing.” European Archives of Oto-Rhino-Laryngology, 2026.
Holsinger, F. C., et al. “Transoral Robotic Surgery in the Multidisciplinary Care of Patients With Oropharyngeal Squamous Cell Carcinoma: ASCO Guideline.” Journal of Clinical Oncology, 2025.
Koyfman, S. A., et al. “Management of the Neck in Squamous Cell Carcinoma of the Oral Cavity and Oropharynx: ASCO Clinical Practice Guideline.” Journal of Clinical Oncology, 2019.
Leddon, J. L., et al. “Phase 2 Trial of Adjuvant Nivolumab Following Salvage Resection in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck.” Clinical Cancer Research, 2022.
Lim, Y. X., et al. “Clinical, Morphologic and Molecular Heterogeneity of HPV-Associated Oropharyngeal Cancer.” Oncogene, 2023.
Maghami, E., et al. “Diagnosis and Management of Squamous Cell Carcinoma of Unknown Primary in the Head and Neck: ASCO Guideline.” Journal of Clinical Oncology, 2020.
Margalit, D. N., et al. “Radiation Therapy for HPV-Positive Oropharyngeal Squamous Cell Carcinoma: An ASTRO Clinical Practice Guideline.” Practical Radiation Oncology, 2024.
Mehanna, H., et al. “Prognostic Implications of P16 and HPV Discordance in Oropharyngeal Cancer (HNCIG-EPIC-OPC): A Multicentre, Multinational, Individual Patient Data Analysis.” Lancet Oncology, 2023.
Mody, M. D., et al. “Head and Neck Cancer.” Lancet, 2021.
National Comprehensive Cancer Network. Head and Neck Cancers (Version 2.2026), 2026.
Nichols, A. C., et al. “Radiotherapy Versus Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma: Final Results of the ORATOR Randomized Trial.” Journal of Clinical Oncology, 2024.
Park, D. A., et al. “Comparative Safety and Effectiveness of Transoral Robotic Surgery Versus Open Surgery for Oropharyngeal Cancer: A Systematic Review and Meta-Analysis.” European Journal of Surgical Oncology, 2020.
Patel, S. N., et al. “Salvage Surgery for Locally Recurrent Oropharyngeal Cancer.” Head & Neck, 2016.
Petrelli, F., et al. “Comparison of Different Treatments for HPV+ Oropharyngeal Carcinoma: A Network Meta-Analysis.” European Archives of Oto-Rhino-Laryngology, 2023.
Quan, D. L., et al. “Surgical Salvage of Human Papillomavirus-Positive Oropharyngeal Cancer: Secondary Analysis of a Randomized Controlled Trial.” Cancer, 2023.
Roselló, À., et al. “Transoral Robotic Surgery vs Open Surgery in Head and Neck Cancer. A Systematic Review of the Literature.” Medicina Oral Patología Oral y Cirugía Bucal, 2020.
Ward, M. C., et al. “Salvage of Locoregionally Recurrent Head and Neck Cancer: An NRG Oncology Working Group Review.” Journal of the National Cancer Institute, 2026.
